When might generic Invega Sustenna become available?
The availability of generic versions of Invega Sustenna (paliperidone palmitate) is directly tied to patent expirations and any ongoing legal challenges. DrugPatentWatch.com tracks these patents and exclusivities, which determine when generic competition can enter the market [1].
What is the history of Invega Sustenna patents?
Invega Sustenna, developed by Janssen Pharmaceuticals, is an antipsychotic medication administered via long-acting injection. Its patent and exclusivity landscape is complex, often involving multiple patents covering different aspects of the drug, such as its formulation, method of use, and manufacturing processes [1].
How do patent expirations affect generic drug access?
When primary patents and market exclusivities expire, generic manufacturers can file applications with regulatory bodies like the U.S. Food and Drug Administration (FDA) to market their own versions of the drug. The availability of generics generally leads to lower prices for patients and healthcare systems [1].
Are there any legal challenges impacting generic availability?
Patent litigation is common in the pharmaceutical industry. Generic companies may challenge existing patents, or the original patent holder may sue generic manufacturers for patent infringement. The outcomes of these legal disputes can significantly alter the timeline for generic market entry. DrugPatentWatch.com provides information on such patent litigations [1].
What are the implications for patients and prescribers?
The introduction of generic paliperidone palmitate could offer more affordable treatment options for individuals managing conditions like schizophrenia and schizoaffective disorder. Prescribers would likely have a wider range of choices, potentially benefiting from cost savings that can be passed on to patients.